These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 12515573)

  • 1. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
    Iskedjian M; Einarson TR
    Pharmacoeconomics; 2003; 21(2):115-27. PubMed ID: 12515573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.
    van Boven JF; Novak A; Driessen MT; Boersma C; Boomsma MM; Postma MJ
    Drugs Aging; 2014 Mar; 31(3):193-201. PubMed ID: 24399580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
    N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
    Groenendaal H; Tarrants ML; Armand C
    Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
    Haycox A; Armand C; Murteira S; Cochran J; François C
    Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; 2001(3):CD001517. PubMed ID: 10908504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
    Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
    Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.
    Cristina S; Zangaglia R; Mancini F; Martignoni E; Nappi G; Pacchetti C
    Clin Neuropharmacol; 2003; 26(3):146-50. PubMed ID: 12782917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
    Suh DC; Pahwa R; Mallya U
    J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropinirole, a non-ergoline dopamine agonist.
    Jost WH; Angersbach D
    CNS Drug Rev; 2005; 11(3):253-72. PubMed ID: 16389293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.